ArticleFrontiers in immunology2026
A multimodal biological margin risk index predicts recurrence after neoadjuvant immunochemotherapy in head and neck squamous cell carcinoma.
Ning Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.